Why Emulsions for Eye Drops? The ocular surface present […]
The ocular surface presents unique barriers to drug delivery: rapid tear turnover dilutes and washes away topical medications, the corneal epithelium restricts penetration of hydrophilic drugs, and patient compliance demands formulations that don’t blur vision or cause stinging. Emulsion-based eye drops address several of these challenges simultaneously ? lipid droplets serve as drug reservoirs that adhere to the ocular surface, the oil phase solubilizes lipophilic drugs that would otherwise require irritating co-solvents, and the lipid component itself provides tear film stabilization that benefits dry eye patients.
High pressure homogenization is the enabling technology for sterile ophthalmic emulsions. The droplet size must be tightly controlled below 1 ?m ? ideally below 500 nm ? to avoid the gritty sensation that patients feel when particles are larger than ~10 ?m, and to ensure physical stability through the 2-3 year shelf life expected of sterile pharmaceutical products. No other emulsification technology matches HPH in achieving submicron droplets with the narrow distribution and batch-to-batch consistency that regulatory agencies require.
Several FDA and EMA-approved ophthalmic products use emulsion technology manufactured by high pressure homogenization:
| Product (Brand) | API | Indication | Emulsion Type | Approximate Droplet Size |
|---|---|---|---|---|
| Restasis | Cyclosporine 0.05% | Dry Eye Disease | Castor oil O/W emulsion | 200-400 nm |
| Cequa | Cyclosporine 0.09% | Dry Eye Disease | Nanomicellar solution | N/A (micellar) |
| Durezol | Difluprednate 0.05% | Post-operative inflammation | Oil-in-water emulsion | 200-500 nm |
| Xelpros | Latanoprost 0.005% | Glaucoma | Oil-in-water emulsion (preservative-free) | 200-400 nm |
| Eysuvis | Loteprednol etabonate 0.25% | Dry Eye (short-term) | Submicron emulsion | 200-400 nm |
The common technical thread across these products: a submicron oil-in-water emulsion manufactured by high pressure homogenization, terminally sterilized by autoclaving, and packaged as a sterile multi-dose or unit-dose product. The emulsion technology itself ? refined over decades of IV fat emulsion manufacturing ? provides the regulatory precedent that makes ophthalmic emulsion development faster and lower risk than novel delivery platforms.
An ophthalmic emulsion formulated for HPH processing typically contains the following components:
The autoclaving step (step 6) is the most demanding test of emulsion stability. Poorly formulated or under-homogenized emulsions will coalesce under the thermal stress of 121?C, showing visible creaming or a shift in droplet size distribution to >1 ?m. A properly homogenized emulsion ? with droplets in the 200-400 nm range and sufficient emulsifier coverage ? survives autoclaving with minimal change in mean diameter (typically <10-20 nm increase).
The trend in ophthalmology is toward preservative-free formulations, driven by evidence that preservatives (especially benzalkonium chloride, BAK) cause cumulative corneal toxicity with long-term use. Preservative-free ophthalmic emulsions present an additional technical challenge: without BAK’s antimicrobial activity, the product must be either terminally sterilized (autoclaved) or aseptically processed and packaged in single-dose units.
High pressure homogenization supports both approaches. For autoclaved products, the homogenizer reduces particle size before the sterilization step ? the thermal stress of autoclaving does not reverse the size reduction. For aseptically processed products, the homogenizer itself can be SIP (Steam-in-Place) sterilized, becoming part of the aseptic boundary.
200-400 nm is the established range for commercial ophthalmic emulsions. Smaller droplets (<200 nm) are acceptable but offer diminishing returns in terms of stability and ocular comfort. Droplets above 500 nm show reduced physical stability during autoclaving and may contribute to visual disturbances (blurring) upon instillation.
Rarely. The droplet size (200-400 nm) is close to the pore size of sterilizing-grade filters (220 nm). Filtration would retain a significant fraction of the emulsion droplets and potentially alter the drug content. Terminal sterilization by autoclaving is the preferred method; aseptic processing with SIP-sterilized equipment is the alternative when the API is heat-sensitive.
The standard stability-indicating assays are: (1) visual inspection for creaming or phase separation, (2) DLS measurement of mean droplet size and polydispersity index (change <20% from pre-autoclave values), (3) pH measurement (typically <0.3 unit shift), and (4) drug content by HPLC (within 95-105% of label claim). These tests are performed on each batch as part of release testing and monitored throughout the shelf-life stability program.
Smallnm 5-10 L/h lab homogenizers can process as little as 30-50 mL of emulsion, making them suitable for formulation screening with expensive APIs. A full factorial DoE (Design of Experiments) testing pressure (600-1000 bar), number of passes (3-8), and emulsifier concentration can be completed with <500 mL of total formulation volume.
Smallnm pharmaceutical homogenizers support the manufacturing workflow that has produced multiple approved ophthalmic emulsion products. Our application team can guide you through formulation feasibility, process development, and equipment qualification for your ocular drug delivery program.
Contact our ophthalmic formulation team to discuss your sterile emulsion manufacturing needs.
Written by
Rethinking Pigment Dispersion: HPH vs Bead Mills The co […]
Liquid Phase Exfoliation: The Scalable Route to 2D Nano […]
Lipid Nanoparticles: The Delivery Vehicle Behind mRNA M […]